Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

Both Moderna and Pfizer-BioNTech manufacture the COVID vaccine in lower doses ... but they're not immune to the virus. "At ...

Non-clinical data showed better response compared to the Omicron XBB.1.5-adapted vaccine. The Health Sciences Authority has ...

1-lineage variants of omicron rather than the XBB.1.5 omicron variant. This is akin to a strain change for a seasonal ...

1-lineage omicron variants of the coronavirus, or SARS-CoV-2. The options include the mRNA vaccines from Pfizer/BioNTech and ...

On July 3, 2024, BioNTech and Pfizer’s Omicron JN.1-adapted COVID-19 vaccine was approved by the European Commission (“EC”). Shortly following approval, the updated vaccines were made ...

BioNTech reported surprisingly strong sales of its COVID-19 vaccine in the third quarter, which reached €1.24 billion ($1.35 billion) and more than doubled the consensus estimate of $652 million.

However, BioNTech continues to innovate, with an omicron-targeting bivalent vaccine launched in 2022 and a new XBB-targeting monovalent vaccine launched in September 2023, as well as ongoing ...

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...

Este artículo estará disponible en español en El Tiempo Latino. Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...